GNR 047

Drug Profile

GNR 047

Alternative Names: GNR-047

Latest Information Update: 09 May 2016

Price : $50

At a glance

  • Originator International Biotechnology Center Generium
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; CD3 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 27 Apr 2016 Preclinical trials in Haematological malignancies in Russia (Parenteral) before April 2016
  • 27 Apr 2016 International Biotechnology Center Generium plans a phase I trial for Haematological malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top